Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer

This post hoc analysis of a multi-institution cohort study assesses the association between androgen receptor perturbation and poorer outcome in patients with TP53 wild-type metastatic castration-resistant prostate cancer who are receiving abiraterone or enzalutamide.

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: De Laere, Bram, Rajan, Prabhakar, Grönberg, Henrik, Dirix, Luc, Lindberg, Johan
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2019
Assuntos:
Research Letter
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6499126/
https://ncbi.nlm.nih.gov/pubmed/31046065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.0869
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados